Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of Refractory Nausea

Trial Profile

Treatment of Refractory Nausea

Phase of Trial: Phase III

Latest Information Update: 16 Mar 2018

At a glance

  • Drugs Netupitant/palonosetron (Primary) ; Dexamethasone; Olanzapine; Prochlorperazine
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 13 Mar 2018 Planned End Date changed from 1 May 2022 to 1 May 2023.
    • 13 Mar 2018 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top